Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GlaxoSmithKline is paying $700 million upfront for a partnership on Alector's lead neurodegeneration assets, latozinemab and AL101, in a deal that could be…
GlaxoSmithKline has agreed to pay South San Francisco's Alector $700 million upfront and as much as $1.5 billion more in milestones for the global rights to…
IDMC determined PROGRESS-AD unlikely to meet its primary endpoint of slowing disease progression; development of nivisnebart for early Alzheimer's discontinued.
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
GSK and Alector entered a global development and commercialization collaboration (announced July 22, 2021; agreement effective August 17, 2021 after HSR clearance) for two progranulin-elevating monoclonal antibodies, latozinemab (AL001) and AL101/GSK4527226 (nivisnebart), targeting neurodegenerative diseases. Alector received $700M upfront ($500M in Q3 2021, $200M in Q1 2022) and was eligible for up to $1.5B in milestones, with 50/50 US profit share and ex-US tiered double-digit royalties. The collaboration thesis has since collapsed: latozinemab missed the clinical co-primary endpoint in the Phase 3 INFRONT-3 trial in FTD-GRN (topline October 21, 2025) and its development was discontinued, prompting Alector to cut ~49% of its workforce; nivisnebart was then discontinued in early Alzheimer's disease after the Phase 2 PROGRESS-AD trial was stopped for futility following an IDMC interim analysis (April 29, 2026). Both lead assets of the collaboration have now failed in the clinic.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Alector, Inc. (this deal) | 2021 | $2.2B | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2021 deals · GlaxoSmithKline plc deals · Neurology deals